12 Month Price Forecast For CSCI
Distance to CSCI Price Forecasts
CSCI Price Momentum
๐ค Considering Cosciens (CSCI)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 10:37 PM UTC
CSCI Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for CSCI (Cosciens).
CSCI is currently trading at $2.87. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSCI Analyst Consensus
CSCI Price Target Range
Latest CSCI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSCI.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
Aug 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
Jul 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
May 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
Apr 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
Mar 28, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
Mar 30, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $1.50 |
Oct 25, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
Nov 9, 2015 | Canaccord Genuity | Buy | Upgrade | $0.00 | |
Apr 14, 2015 | H.C. Wainwright | Buy | Upgrade | $0.00 | |
Jul 17, 2014 | H.C. Wainwright | Buy | Initiates | $0.00 | |
Jul 25, 2013 | Euro Pacific Capital | Hold | Initiates | $0.00 | |
Jan 3, 2013 | McNicoll Lewis Vlak | Buy | Upgrade | $0.00 | |
Dec 31, 2012 | Canaccord Genuity | Hold | Maintains | $2.50 | |
Oct 12, 2012 | Bloom Burton & Co. | Sell | Maintains | $2.00 |
Stocks Similar to Cosciens Biopharma Inc
The following stocks are similar to Cosciens based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cosciens Biopharma Inc (CSCI) Financial Data
Cosciens Biopharma Inc has a market capitalization of $8.96M with a P/E ratio of -1.5x. The company generates $4.83M in trailing twelve-month revenue with a 41.1% profit margin.
Revenue growth is +62,266.7% quarter-over-quarter, while maintaining an operating margin of -258.4% and return on equity of -100.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cosciens Biopharma Inc (CSCI) Company Overview
About Cosciens Biopharma Inc
Develops biopharmaceuticals and diagnostic tests.
COSCIENS Biopharma Inc. focuses on developing and commercializing therapeutics and diagnostic tests, primarily through licensing agreements and partnerships with other firms and universities. The company generates revenue by selling its lead product, Macrilen, for growth hormone deficiency diagnosis, alongside other therapeutic products in various stages of development.
The company operates internationally, with a presence in Canada, the U.S., and several European countries. It has ongoing preclinical trials for treatments related to chronic hypoparathyroidism and amyotrophic lateral sclerosis, indicating a diverse pipeline in the biopharmaceutical space. COSCIENS Biopharma was previously known as Aeterna Zentaris Inc. and rebranded in August 2024.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.
Country
Canada
IPO Year
2000
Website
www.cosciensbio.comCosciens Biopharma Inc (CSCI) Latest News & Analysis
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
1 month agoThe company is focused on developing and commercializing natural-based products aimed at enhancing health and wellness.
The focus on natural-based health products may indicate growth potential and market demand, potentially driving revenue and stock performance for the company.
COSCIENS Biopharma Inc. reported a cash balance of $20 million as of September 30, 2024, following merger integration with Ceapro Inc. and ongoing evaluations of its product pipeline.
The successful merger integration and strong cash position suggest COSCIENS Biopharma is well-positioned for growth, potentially increasing investor confidence and stock value.
COSCIENS Biopharma Inc. announced the immediate resignation of Carolyn Egbert from its Board of Directors, as of October 8, 2024.
Carolyn Egbert's resignation from COSCIENS' Board may signal potential instability or strategic shifts, impacting investor confidence and stock performance.
COSCIENS Biopharma Inc. has appointed Pierre Labbรฉ to its board and as Chair of the Audit Committee, following Dennis Turpin's resignation, effective October 1, 2024.
Leadership changes can impact company strategy and investor confidence. Pierre Labbรฉ's appointment may signal a shift in governance or focus, influencing stock performance and investor sentiment.
COSCIENS Biopharma Inc. (NASDAQ: CSCI, TSX: CSCI) announced updates on its merger integration with Ceapro Inc., including management team changes and business advancements.
Merger updates and management changes can significantly impact COSCIENS' operational efficiency and market position, influencing investor sentiment and stock performance.
COSCIENS Biopharma's Phase 3 DETECT-trial for macimorelin in diagnosing Childhood Onset Growth Hormone Deficiency did not meet its primary efficacy endpoint, despite confirming safety in children.
The failure to meet primary efficacy endpoints may lead to regulatory setbacks and impact COSCIENS Biopharma's stock performance, influencing investor confidence and potential market value.
Frequently Asked Questions About CSCI Stock
What is Cosciens Biopharma Inc's (CSCI) stock forecast for 2025?
Analyst forecasts for Cosciens Biopharma Inc (CSCI) are not currently available. The stock is trading at $2.87.
Is CSCI stock a good investment in 2025?
Analyst ratings for CSCI are not currently available. The stock is currently trading at $2.87. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CSCI stock?
Price predictions from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.87.
What is Cosciens Biopharma Inc's business model?
COSCIENS Biopharma Inc. focuses on developing and commercializing therapeutics and diagnostic tests, primarily through licensing agreements and partnerships with other firms and universities. The company generates revenue by selling its lead product, Macrilen, for growth hormone deficiency diagnosis, alongside other therapeutic products in various stages of development.
What is the highest forecasted price for CSCI Cosciens Biopharma Inc?
Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.87.
What is the lowest forecasted price for CSCI Cosciens Biopharma Inc?
Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.87.
What is the overall CSCI consensus from analysts for Cosciens Biopharma Inc?
Analyst ratings for CSCI are not currently available. The stock is trading at $2.87.
How accurate are CSCI stock price projections?
Stock price projections, including those for Cosciens Biopharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.